Medical directoryActive ingredient
Orforglipron
An investigational small-molecule oral GLP-1 agonist, without the dosing restrictions of oral semaglutide. NOT licensed.
Content reviewed by Dr. David Céspedes
Medical guides
Orforglipron (Foundayo), approved by the FDA: the first GLP-1 pill that can be taken without food or water restrictions
ReadOrforglipron (Foundayo): the first GLP-1 pill with no restrictions, and why it isn't available in Spain
ReadRetatrutide: what its phase 3 trial found, and why you can't get hold of it
ReadCagriSema: what it is, what the REDEFINE trials found and why it disappointed
Read
Keep reading
This entry is for information. Your case requires an individual medical assessment.